Business/Regulatory

Patient perspectives generate specific outcome objectives, what they are willing to do to achieve them, the risks they are willing to bear, and the costs they are willing to pay. The same could be said about payers.
Merck announced that they are stopping their head to head comparative phase 3 study in advanced melanoma early since they met their primary endpoint ahead of schedule. In the competitive world of big pharma, that is considered a slam dunk.
The study’s primary endpoint—rate of complete remission (CR)—was not significantly different between the two groups.
Endo International has confirmed they are offering to pay $175 per share (i.e., $11 Billion) or an 11% premium over the offer made by Valeant.
Kevin Lee, PhD, chief scientific officer of Pfizer's rare disease research unit discusses how the company works with patient advocacy groups to develop orphan drugs.
Kevin Lee, PhD, chief scientific officer of Pfizer's rare disease research unit discusses Pfizer's philosophy on orphan drug development.
Rare Disease Community is a collaborative one between patients and industry. In this exclusive interview with Rare Disease Report, Kevin Lee, PhD, chief scientific officer of Pfizer's rare disease research unit discusses some of the programs Pfizer has established to help the drug developers learn what the patients want and need.
2014 was a difficult year for Sarepta.
Shire has bought Meritage, a privately-held company for their oral budesonide suspension that is in phase 3 development.
Two companies were recently given 10-year National Institute of Neurological Disorders and Stroke (NINDS) awards from the National Institutes of Health (NIH) to advance drug development and provide manufacturing services for potential treatments for neurological disorders.
External Resources

MJH Associates
AJMC
Cure
HCPLive
OncLive
Pharmacy Times
Specialty Pharmacy Times
Physicians' Education Resource
Internal Resources

Medicine
Advocacy
Business/Regulratory
Events
Conferences
Connect With Us:

About Us
Advertise
Careers
Contact Us
Privacy Policy
Sponsor
Terms and Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright Rare Disease Report 2015
Intellisphere, LLC. All Rights Reserved.